Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS)
暂无分享,去创建一个
J. Fuge | W. Schütte | K. Milger | H. Suhling | H. Timmermann | Andreas Mühle | D. Skowasch | S. Korn | Claudia Feder
[1] I. Dávila,et al. Response to monoclonal antibodies in asthma: definitions, potential reasons for failure and therapeutic options for suboptimal response. , 2022, Journal of investigational allergology & clinical immunology.
[2] T. Welte,et al. Overall response to anti-IL5/anti-IL5Rα treatment in severe asthma does not depend on initial bronchodilator responsiveness. , 2022, Journal of Allergy and Clinical Immunology: In Practice.
[3] J. Virchow,et al. Prevalence of Patients with Uncontrolled Asthma Despite NVL/GINA Step 4/5 Treatment in Germany , 2022, Journal of asthma and allergy.
[4] J. Virchow,et al. Safety of combining biologics in severe asthma: Asthma‐related and unrelated combinations , 2022, Allergy.
[5] J. Virchow,et al. Disease-modifying anti-asthmatic drugs , 2022, The Lancet.
[6] K. Rabe,et al. Dupilumab reduces oral corticosteroid use in patients with corticosteroid-dependent severe asthma: An analysis of the phase 3, open-label extension TRAVERSE trial. , 2022, Chest.
[7] G. Koppelman,et al. Biologic Therapies for Severe Asthma. , 2022, The New England journal of medicine.
[8] I. Pavord,et al. Choosing a Biologic For Patients With Severe Asthma , 2021, The Journal of Allergy and Clinical Immunology: In Practice.
[9] E. Bel,et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. , 2021, The Lancet. Respiratory medicine.
[10] J. Upham,et al. Defining a severe asthma super-responder: findings from a Delphi process. , 2021, The journal of allergy and clinical immunology. In practice.
[11] H. Watz,et al. Small Airway Dysfunction Links Asthma Severity with Physical Activity and Symptom Control. , 2021, The journal of allergy and clinical immunology. In practice.
[12] E. Bleecker,et al. German regional variation of acute and high oral corticosteroid use for asthma , 2020, The Journal of asthma : official journal of the Association for the Care of Asthma.
[13] S. Loukides,et al. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[14] M. Lommatzsch,et al. Oral corticosteroid prescription for asthma by general practitioners: A three-year analysis in Germany. , 2020, Respiratory medicine.
[15] K. Bergmann,et al. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma , 2020, Journal of asthma and allergy.
[16] T. Welte,et al. Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy. , 2020, The journal of allergy and clinical immunology. In practice.
[17] A. Douiri,et al. Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. , 2020, Chest.
[18] G. Canonica,et al. EAACI Biologicals Guidelines—Recommendations for severe asthma , 2020, Allergy.
[19] E. V. van Roon,et al. Prediction of response to biological treatment with monoclonal antibodies in severe asthma. , 2020, Biochemical pharmacology.
[20] I. Pavord,et al. An Expert Consensus Framework for Asthma Remission as a Treatment Goal. , 2019, The Journal of allergy and clinical immunology.
[21] C. Taube,et al. Prevalence of oral corticosteroid use in the German severe asthma population , 2019, ERJ Open Research.
[22] J. Krings,et al. Role of Biologics in Asthma , 2019, American journal of respiratory and critical care medicine.
[23] E. Bleecker,et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma , 2018, European Respiratory Journal.
[24] D. Price,et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study , 2018, Journal of asthma and allergy.
[25] T. Welte,et al. Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response , 2018, BMC Pulmonary Medicine.
[26] K. Rabe,et al. Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.
[27] K. Rabe,et al. Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.
[28] I. Pavord,et al. Severe eosinophilic asthma: a roadmap to consensus , 2017, European Respiratory Journal.
[29] I. Pavord,et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.
[30] Jacques P. Brown,et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy , 2013, Allergy, Asthma & Clinical Immunology.
[31] Mark Kosinski,et al. The minimally important difference of the Asthma Control Test. , 2009, The Journal of allergy and clinical immunology.
[32] Philip Marcus,et al. Development of the asthma control test: a survey for assessing asthma control. , 2004, The Journal of allergy and clinical immunology.